Fondazione Italiana Linfomi Ets — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

3 Recruiting

8 Completed trials

1 Countries active

30 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 8 Phase I/II: 2

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Mantle cell lymphoma 3 Diffuse large B-cell lymphoma 3 Anaplastic large cell lymphoma T- and null-cell types 1 Peripheral T-cell lymphoma unspecified 1 Follicular lymphoma 1 Mantle cell lymphoma refractory 1 Angioimmunoblastic T-cell lymphoma 1 Mantle cell lymphoma recurrent 1

Top IMPs

GOLCADOMIDE 1 MOSUNETUZUMAB 1 ROMIDEPSIN 1 ZANUBRUTINIB 1

All trials

13 total

PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li… Pending

2025-521666-10-01 Phase II 1 country
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed afte… Pending

2025-523428-39-00 Phase II 1 country
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non… Recruiting

2023-506206-38-00 Phase II 1 country GOLCADOMIDE
phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate… Recruiting

2024-511631-10-00 Phase I/II 1 country
An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit… Recruiting

2024-511635-94-00 Phase II 1 country
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended

2023-506049-52-00 Phase II 1 country MOSUNETUZUMAB; ZANUBRUTINIB
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended

2024-511633-35-00 Phase II 1 country
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Phase III 1 country
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Phase III 1 country
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended

2024-511641-18-00 Phase II 1 country
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab al… Ended

2024-511640-11-00 Phase III 1 country
Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended

2024-511533-35-00 Phase II 1 country
ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER… Ended

2024-511639-83-00 Phase I/II 1 country ROMIDEPSIN

Showing 1–13 of 13 trials

← All sponsors A–Z